Together we are stronger

Website funded by Pharnext

We are delighted to acknowledge the very kind support of French pharmacological company, Pharnext, for their donation which allowed us to have this website created.



Pharnext are currently developing a new drug to treat CMT Type 1a.  The drug is in Phase 3 trials across Europe and the States currently, and the results of this trial will be available sometime in 2018.

You can read more about PXT3003 here –

Donations Accepted